EndoPredict is the only gene expression test providing 10 years’ personalized chemotherapy benefit for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1-7 – and the only second generation test with level of evidence 1A data.8,9
Almost all women with ER positive/HER2 negative breast cancer will receive at least 5 years of endocrine therapy. But, the question of who will benefit from adjuvant chemotherapy is still challenging.
Clinicians and their patients can use EndoPredict as a prognostic tool for deciding breast cancer treatment, improving quality of life for more women with ER positive/HER2 negative early-stage breast cancer.
If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.
Chemotherapy benefit was validated in a large cross-cohort study4 with over 3,700 patients with ER positive, HER2 negative breast cancer:
These data show clearly separated curves and an individual chemotherapy benefit for EPclin high-risk patients, which were proven by a significant test for interaction.
The EPclin Risk Score is calculated for every patient, presented as a continuous curve. The cut-off for low- and high-risk aligns with the 10% guideline-recommended, acceptable risk of breast cancer recurrence. Chemotherapy benefit at the cut-off is about 3%, roughly comparable to the risk of more serious side effects from chemotherapy.
Clinicians can confidently use each woman’s EPclin Risk Score to guide shared decision making with regards to treatment options. Learn how to interpret EPclin Risk Score.
Validated in five prospective-retrospective studies of more than 3,500 patients.1-7 Initial results of a randomized controlled prospective phase III study (UNIRAD) were released at SABCS 2021.8
Recommended by many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGTM, AGO, HAS, NICE, SEOM, AIOM, CACA-CBCS, CcO.
The EndoPredict animated app can show you how various gene activities in the tumor influence the prognosis and how the molecular fingerprint and tumor size and nodal status contribute to the final EndoPredict result.
EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.